Wikipedia

Respiratory syncytial virus

(Redirected from HRSV)

Respiratory syncytial virus (RSV),[a] also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus.[2] Its name is derived from the large cells known as syncytia that form when infected cells fuse.[2][3]

Orthopneumovirus hominis
Filamentous RSV particles
Electron micrograph of filamentous RSV particles
Virus classification Edit this classification
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Negarnaviricota
Class: Monjiviricetes
Order: Mononegavirales
Family: Pneumoviridae
Genus: Orthopneumovirus
Species:
Orthopneumovirus hominis
Synonyms[1]
  • Human respiratory syncytial virus (hRSV)
  • Respiratory syncytial virus (RSV)

RSV is a common cause of respiratory hospitalization in infants, and reinfection remains common in later life, though often with less severity. It is a notable pathogen in all age groups. Infection rates are typically higher during the cold winter months, causing bronchiolitis in infants, common colds in adults, and more serious respiratory illnesses, such as pneumonia, in the elderly and immunocompromised.[4]

RSV can cause outbreaks both in the community and in hospital settings. Following initial infection via the eyes or nose, the virus infects the epithelial cells of the upper and lower airway, causing inflammation, cell damage, and airway obstruction.[2] A variety of methods are available for viral detection and diagnosis of RSV including antigen testing, molecular testing, and viral culture.[3]

Other than vaccination, prevention measures include hand-washing and avoiding close contact with infected individuals.[5] The detection of RSV in respiratory aerosols,[6] along with the production of fine and ultrafine aerosols during normal breathing, talking,[7] and coughing,[8] and the emerging scientific consensus around transmission of all respiratory infections,[9] airborne precautions may also be required for reliable protection. In May 2023, the US Food and Drug Administration (FDA) approved the first RSV vaccines, Arexvy (developed by GSK plc) and Abrysvo (Pfizer).[10][11] The prophylactic use of palivizumab or nirsevimab (both are monoclonal antibody treatments) can prevent RSV infection in high-risk infants.[5][12]

Treatment for severe illness is primarily supportive, including oxygen therapy and more advanced breathing support with continuous positive airway pressure (CPAP) or nasal high flow oxygen, as required. In cases of severe respiratory failure, intubation and mechanical ventilation may be required. Ribavirin is an antiviral medication licensed for the treatment of RSV in children.[13] RSV infection is usually not serious, but it can be a significant cause of morbidity and mortality in infants and in adults, particularly the elderly and those with underlying heart or lung diseases.

History

edit

RSV was discovered in 1956 when researchers isolated a virus from a population of chimpanzees with respiratory illness. They named the virus chimpanzee coryza agent (CCA).[14] In 1957, this same virus was identified by Robert M. Chanock in children with respiratory illness.[15] Studies of human antibodies in infants and children revealed that the infection was common in early life.[16] The virus was later renamed human orthopneumovirus, or human respiratory syncytial virus (hRSV).[17][18]

Several other pneumoviruses show great similarity to hRSV. Bovine RSV (bRSV) shares approximately 80% of its genome with hRSV. It also shares hRSV's predilection for the young, causing more severe disease in calves less than six months old. Because bRSV-infected calves have almost identical symptoms to hRSV-infected children, they have proven to be an important animal model in RSV research.[19]

Signs and symptoms

edit

RSV infection can present with a wide variety of signs and symptoms that range from mild upper respiratory tract infections (URTI) to severe and potentially life-threatening lower respiratory tract infections (LRTI) requiring hospitalization and mechanical ventilation.[19] While RSV can cause respiratory tract infections in people of all ages and is among common childhood infections, its presentation often varies between age groups and immune status.[4] Reinfection is common throughout life, but infants and the elderly remain at risk for symptomatic infection.[19]

Children

edit

Nearly all children in the United States experience at least one RSV infection before two years of age.[20] Childhood RSV infections are fairly self-limited with typical upper respiratory tract signs and symptoms, such as nasal congestion, runny nose, cough, and low-grade fever.[4][20] Inflammation of the nasal mucosa (rhinitis) and throat (pharyngitis), as well as redness of the eyes (conjunctival infection), may be seen on exam.[3] Approximately 15–50% of children will go on to develop more serious lower respiratory tracts infections, such as bronchiolitis, viral pneumonia, or croup.[19][21] Infants are at the highest risk of disease progression.[3]

Video: Respiratory Syncytial Virus and Bronchiolitis

Bronchiolitis is a common lower respiratory tract infection characterized by inflammation and obstruction of the small airways in the lungs.[22] While several viruses can cause bronchiolitis, RSV is responsible for about 70% of cases.[4] It usually presents with 2 to 4 days of runny nose and congestion followed by worsening cough, noisy breathing, tachypnea (fast breathing), and wheezing.[20] As infants work harder to breathe, they can also show signs of respiratory distress, such as subcostal retractions (when the belly pulls under the ribcage), intercostal retractions (when the muscles between the ribs pull inward), grunting, and nasal flaring.[19] If the child has not been able to feed adequately, signs of dehydration may also be present.[20] Fever may be present, but high-grade fever is uncommon.[19] Crackles and wheezing can often be heard on auscultation, and oxygen saturation levels may be decreased.[22]

In very young infants under six weeks of age, and particularly in premature infants, signs of infection may be less specific. They may have minimal respiratory involvement. Instead, they may exhibit decreased activity, irritability, poor feeding, or breathing with difficulties. This can also be accompanied by apneic spells, or brief pauses in breathing.[4][23]

Adults

edit

Reinfection with RSV remains common throughout life. Reinfection in adulthood often produces only mild to moderate symptoms indistinguishable from the common cold or sinus infection.[4] Infection may also be asymptomatic. If present, symptoms are generally isolated to the upper respiratory tract: runny nose, sore throat, fever, and malaise. In the vast majority of cases, nasal congestion precedes the development of cough.[3] In contrast to other upper respiratory infections, RSV is also more likely to cause new onset wheeze in adults.[3] About 25% of infected adults will progress to significant lower respiratory tract infection, such as bronchitis or tracheobronchitis.[19]

While RSV very rarely causes severe disease in healthy adults, it can cause morbidity and mortality in the elderly and in those with underlying immune compromise or cardiopulmonary disease. Older adults have a similar presentation to younger adults but tend to have greater symptom severity with increased risk of lower respiratory tract involvement. In particular, the elderly are more likely to experience pneumonia, respiratory distress, and death.[3]

Immunocompromised

edit

In both adults and children, those who are immunocompromised are at an increased risk of severe infection with RSV. Infected individuals in this group are more likely to progress from upper to lower respiratory tract involvement and have prolonged viral shedding.[24] Symptom severity seems to be closely related to the extent of immune suppression. Those who have undergone hematopoietic stem cell transplant (HSCT), intensive chemotherapy, and lung transplant are particularly susceptible.[3][25] Bone marrow transplant patients appear to be at highest risk, especially prior to marrow engraftment. In this group, RSV infection carries a nearly 80% risk of both pneumonia and death.[3][26]

Elderly

edit

RSV or Respiratory syncytial (sin-SISH-uhl) virus affects many populations differently. The most at risk population for RSV complications are older adults and those with underlying medical conditions or immunocompromised individuals.[27] Between 60,000-160,000 older adults in the United States are hospitalized annually with RSV. Between 6,000-10,000 of older adults die from RSV infection each year.[28] Additionally RSV  can ". . . lead to worsening of serious conditions such as, Asthma, Chronic obstructive pulmonary disease (COPD) – a chronic disease of the lungs that makes it hard to breathe, and even Congestive heart failure – when the heart can't pump enough blood and oxygen through the body."[28] Expedient and proper medical care is important for older adults as waiting, or receiving a misdiagnosis can be associated with increased risk of complications. As of August 2023, adults aged 60 years and older qualify for vaccination against RSV in Canada and the United States.[28]

Complications

edit
Population Complications of RSV infection
Children Short term, hospitalized children are at risk of developing:[4]

Long term, children are at risk of developing the following chronic conditions that may persist into adulthood:

  • Asthma and recurrent wheezing, particularly among those with severe RSV infection in early life[29][30]
  • Allergy[3]
  • Acute neurologic complications[31]
Adults The following are more common in elderly adults or those with underlying immunocompromise or cardiopulmonary conditions:
Immunocompromised Some immunocompromised groups are at higher risk of specific complications, such as:

Risk factors

edit

Risk factors for development of severe lower respiratory tract infection with RSV vary by population.

Population Risk factors for progression to lower respiratory infection with RSV
Children[32]
  • Prematurity
  • Low birth weight
  • Male sex
  • Having older siblings
  • Maternal smoking during pregnancy
  • History of atopy (tendency to develop allergic diseases)
  • No breastfeeding
  • Household crowding
  • Congenital heart or lung disease
Adults and elderly[4]
  • Older age (>65 years of age)
  • Chronic heart or lung disease (especially COPD)
  • Functional disability
  • Residence in a care home
Immunocompromised[24][33]

Virology

edit
 
A phylogenetic tree of the pneumovirus and paramyxovirus families

Taxonomy

edit

RSV is a negative-sense, single-stranded RNA virus.[2] The scientific name for this viral species is human orthopneumovirus. This is synonymous with human respiratory syncytial virus (hRSV), which is often shortened to just RSV.[34] It belongs to the genus Orthopneumovirus, family Pneumoviridae, order Mononegavirales.[2] Its name comes from the fact that F proteins on the surface of the virus cause neighboring cell membranes to merge, creating large multinucleated syncytia.[3]

Antigenic subtypes

edit

RSV is divided into two antigenic subtypes, A and B, based on the reactivity of the F and G surface proteins to monoclonal antibodies.[2][3] The subtypes tend to circulate simultaneously within local epidemics, although subtype A tends to be more prevalent.[26] Generally, RSV subtype A (RSVA) is thought to be more virulent than RSV subtype B (RSVB), with higher viral loads and faster transmission time.[2][3] To date, 16 RSVA and 22 RSVB clades have been identified.[2] Among RSVA, the GA1, GA2, GA5, and GA7 clades predominate; GA7 is found only in the United States.[2] Among RSVB, the BA clade predominates worldwide.[2]

Genome

edit
 
RSV structure and genome organization. (a) ~150 nm RSV virion particle and (b) single-stranded negative-sense RNA genome consisting of 10 genes (NS1-NS2-N-P-M-SH-G-F-M2-L).

RSV has a negative-sense, single-stranded RNA genome.[2] The genome is linear and approximately 15,000 nucleotides in length.[3] It has 10 genes encoding for 11 proteins.[2][4] The gene order is NS1-NS2-N-P-M-SH-G-F-M2-L, with the NS1 and NS2 gene serving as nonstructural promoter genes.[35]

 
Electron micrograph of RSV particle, which has variable shapes

Structure and proteins

edit
 
Electron micrograph of RSV

RSV is a medium-sized (~150 nm) enveloped virus. While many particles are spherical, filamentous species have also been identified.[2][3] The genome rests within a helical nucleocapsid and is surrounded by matrix protein and an envelope containing viral glycoproteins.[36] There are 11 proteins, described further in the table below.

RSV proteins and their function and location in the virion[2][37]
Location in the Virion Protein Alternative Name Function Additional Information
Lipid envelope (transmembrane surface proteins) G Glycoprotein Viral attachment to ciliated cells of the host airway F and G glycoproteins are the two major surface proteins that control viral attachment and the initial stages of infection. F and G proteins are also the primary targets for neutralizing antibodies during natural infection.
F Fusion protein Fusion of viral and host cell membranes; syncytium formation
SH Small hydrophobic protein Viroporin; ion channel Participates in cell fusion, but no known neutralizing epitope
Inner envelope face M Matrix protein Assembly
Ribonucleocapsid N Nuceloprotein RNA-binding Involved in genome transcription, RNA replication, and particle budding
P Phosphoprotein Phosphorylation
L "Large" protein RNA-dependent RNA polymerase
M2-1 - Transcription processivity factor
Regulatory M2-2 - Regulation of transcription / RNA replication
Nonstructural NS-1 - Involved in evasion of the innate immune system Act by inhibiting apoptosis and inhibiting Type I IFN signaling
NS-2 -

G protein

edit
 
False-color artistic rendering of RSV. G- glycoproteins are shown in light blue, with F-glycoproteins in orange.
Main article: Respiratory syncytial virus G protein
 
An illustration of the respiratory syncytial virus (RSV) in cross-section landing on a respiratory endothelial cell in humans. A nuclear protein core capped by large L proteins is depicted with single-stranded RNA (colored purple). The virion exterior is populated by F and G proteins, while its interior is lined by M2-1 and M proteins. G proteins are shown as tangled tubular structures, and F proteins are represented as structures resembling drumsticks.

Surface protein G (glycoprotein) is primarily responsible for viral attachment to host cells.[37] This protein is highly variable between strains.[26] G protein exists in both membrane-bound and secreted forms.[3][37] The membrane-found form is responsible for attachment by binding to glycosaminoglycans (GAGs), such as heparan sulfate, on the surface of host cells.[2][4][3] The secreted form acts as a decoy, interacting with antigen presenting cells to inhibit antibody-mediated neutralization.[3][37] G protein also contains a CX3C fractalkine-like motif that binds to the CX3C chemokine receptor 1 (CX3CR1) on the surface of ciliated bronchial host cells.[2][4] This binding may alter cellular chemotaxis and reduce the migration of immune cells into the lungs of infected individuals.[37] G protein also alters host immune response by inhibiting signaling from several toll-like receptors, including TLR4.[4][37]

F protein

edit

Surface protein F (fusion protein) is responsible for fusion of viral and host cell membranes, as well as syncytium formation between viral particles.[37] Its sequence is highly conserved between strains.[26] While viral attachment appears to involve both F and G proteins, F fusion occurs independently of G.[37] F protein exists in multiple conformational forms.[2][4] In the prefusion state (PreF), the protein exists in a trimeric form and contains the major antigenic site Ø.[2] Ø serves as a primary target of neutralizing antibodies in the body.[4] After binding to its target on the host cell surface (its exact ligand remains unclear), PreF undergoes a conformational change during which Ø is lost.[2][4] This change enables the protein to insert itself into the host cell membrane and leads to fusion of the viral and host cell membranes.[2] A final conformational shift results in a more stable and elongated form of the protein (postfusion, PostF).[4] Opposite of the RSV G protein, the RSV F protein also binds to and activates toll-like receptor 4 (TLR4), initiating the innate immune response and signal transduction.[2][37]

 
Schematic image of RSV life cycle

Replication cycle

edit

Following fusion of the viral and host cell membranes, the viral nucleocapsid (containing the viral genome) and the associated viral polymerase are delivered into the host cell cytoplasm. Transcription and translation both occur within the cytoplasm. RNA-dependent RNA polymerase transcribes the genome into 10 segments of messenger RNA (mRNA) which is translated into structural proteins by host cell machinery. During replication of the negative-sense viral genome, RNA-dependent RNA polymerase synthesizes a positive-sense complement called the antigenome. This complementary strand is used as a template to construct genomic negative-sense RNA, which is packaged into nucleocapsids and transported to the plasma membrane for assembly and particle budding.[36]

Mechanism

edit

Transmission

edit

RSV is highly contagious and can cause outbreaks from both community and hospital transmission.[3] For each person infected with RSV, it is estimated that an average of 5 to 25 uninfected people will become infected.[38] RSV can spread when an infected person coughs or sneezes, releasing contaminated droplets into the air. Transmission usually occurs when these droplets come into contact with another person's eyes, nose, or mouth.[39] As with all respiratory pathogens once presumed to transmit via respiratory droplets, it is highly likely to be carried by the aerosols generated during routine breathing, talking, and even singing.[9] RSV can also live for up to 25 minutes on contaminated skin (i.e. hands) and several hours on other surfaces like countertops and doorknobs.[3][38] It has an incubation period of 2 to 8 days.[3] Once infected, people are usually contagious for 3 to 8 days. In infants and in people with weakened immune systems, however, the virus may continue to spread for up to 4 weeks (even after they are no longer showing symptoms).[39]

 
Lumen of an obstructed bronchiole containing cellular debris and aggregates of sloughed epithelial cells

Pathogenesis

edit

Following transmission through the nose or eyes, RSV infects ciliated columnar epithelial cells of the upper and lower airway.[3] RSV continues to replicate within these bronchial cells for about 8 days.[2] After the first several days, RSV-infected cells will become more rounded and ultimately slough into the smaller bronchioles of the lower airway.[2] This sloughing mechanism is also thought to be responsible for the spread of virus from the upper to lower respiratory tract.[2] Infection causes generalized inflammation within the lungs, including the migration and infiltration of inflammatory cells (such as monocytes and T-cells), necrosis of the epithelial cell wall, edema, and increased mucous production.[3] Inflammation and cell damage tends to be patchy rather than diffuse.[3] Together, the sloughed epithelial cells, mucous plugs, and accumulated immune cells cause obstruction of the lower airway.[2][3]

Reinfection

edit

After recovery of "respiratory diseases associated with RSV infection, the virus interferes with the establishment of immunological memory, which leads to recurrent reinfections."[40] An estimated of "36% of individuals" can be reinfected with RSV "at least once, during the winter season."[40] Reinfections like these can be a result of "an initial encounter with RSV" that "fails to initiate adequate humoral and cellular immune responses to generate protective memory lymphocytes."[40]

RSV reinfection can happen throughout life. As a result, it can cause "winter/early spring epidemics in temperate regions, but synchronization of RSV activity can vary widely" depending on the region that an individual lives in.[40] Usually, "unless immunocompromised," adults have mild symptoms when becoming reinfected.[41] The mild symptoms tend to be restricting upper airways. However, individuals that are younger are extremely vulnerable to developing "severe symptoms," which typically involve the lower airways.[41] Since infants have smaller airways than children do, "they might be obstructed by inflammation, edema, and mucus."[41] This can contribute to developing a "more severe lower respiratory tract illness."[41] As mentioned, RSV reinfection is frequent among all ages and the type of host response to reinfection can determine "which children will develop persistent wheezing and possibly asthma."[41] It is possible that the age you are infected with RSV can be a vital factor in "determining the phenotype of airway response to subsequent RSV infection."[41]

Immune escape

edit

Genetic variations in viral epitopes and adjacent regions affect protein folding, post-transcriptional modifications, and antigenic processing, influencing B and T cell immunity during viral infections.[42] This alteration in conformation can lead to immune evasion, potentially impacting disease severity, outbreaks, and reinfections. Notably, the variability observed in the G gene, followed by the SH and F genes, suggests a correlation between structural differences in proteins and their immunogenicity.[42] Specifically, the irregular curl and low bond energy of the G protein make it prone to conformational changes, affecting its immunogenicity and potentially modulating the immune response.[42]

Different genotypes of RSV exhibit variations in the structural conformation of key proteins such as G, SH, and F, impacting immune responses. The emergence of novel genotypes like ON1 and BA9 is associated with distinct structural differences, particularly in the G protein, which may contribute to immune evasion. Evidence suggests that RSV glycoprotein G plays a crucial role in immune modulation during infection, affecting cytokine expression and the antiviral response.[42] In addition, positive selection pressure drives the dominance of certain genotypes over others, potentially driven by mutations within specific regions of the G gene.[citation needed]

The F protein is a major target for neutralizing antibodies, but its variability enables viral evasion from neutralization, affecting the efficacy of antibodies like Palivizumab.[42] Cross-reactions between RSV subtypes and genotypes are observed, but immune responses are subtype or genotype-specific, indicating the impact of gene mutations, particularly in the G protein, on immune evasion. Additionally, differences in cytokine expression and immune cell responses highlight the complexity of immune interactions during RSV infection. Genomic variations in RSV, particularly in proteins like G and F, influence immune responses and contribute to immune evasion. This multifaceted immunomodulatory arsenal likely contributes to RSV's ability to cause mild respiratory symptoms in most cases, yet it poses a severe threat to vulnerable populations such as infants and the elderly, potentially leading to life-threatening lung disease characterized by immune dysregulation. RSV has evolved numerous strategies to evade the host's antiviral response, with over half of its proteins exerting immunomodulatory effects.

Diagnosis

edit

Laboratory diagnosis

edit

A variety of laboratory tests are available for the diagnosis of RSV infection. While the American Academy of Pediatrics (AAP) does not routinely recommend the use of lab testing to diagnose RSV bronchiolitis (for which the treatment is largely supportive),[5] confirmation of RSV infection may be warranted in high-risk groups if the result will guide clinical decisions. Common identification techniques include antigen testing, molecular testing, and viral culture.[3]

Antigen testing

edit

Antigen testing involves detection of RSV antigen fragments (or pieces of molecular viral structures), usually from an nasopharyngeal swab or aspirate. This can be accomplished either by viewing fluorescently labeled antigens under a microscope (direct fluorescence assay, or DFA) or using a commercially available rapid antigen detection test (RADT).[3] Overall, antigen testing is highly sensitive in young children (80–90%) but substantially less reliable in older children and adults, who have less viral shedding.[3] Antigen tests are also subject to higher false positive rates outside of the peak RSV season, such as in the summer months. In these scenarios, the use of either viral culture or nucleic acid amplification testing (NAAT) may aid in an accurate RSV diagnosis.[citation needed]

Molecular testing

edit

Molecular assays, such as nucleic acid amplification tests (NAATs), enable sensitive detection of very small amounts of virus in nasopharyngeal swabs and aspirates. NAAT assays such as polymerase chain reaction (PCR) detect virus-specific genetic material, rather than viral antigens. They have a sensitivity and specificity approaching 100%.[43] However, they tend to be more expensive and require more complex equipment than other testing methods, making them less practical in resource limited areas. Molecular testing for RSV is not routinely recommended for all people with respiratory symptoms. However, it may be recommended for those at high risk of RSV complications, such as infants, older adults, and people with chronic medical conditions.[medical citation needed] RT-PCR has a sensitivity of 90-95% and a specificity of 98-99%, while LAMP has a sensitivity of 95-100% and a specificity of 99-100%.[citation needed]

  • Polymerase chain reaction (PCR) is type of NAAT which allows a very small sample of genetic material to be rapidly amplified into millions of copies for study. PCR is more sensitive than either antigen testing or viral culture.[43] Therefore, it can be used to detect virus in those with lower viral shedding, such as older children and adults. It may also be used to detect the disease earlier in at-risk individuals (such as hospitalized or immunocompromised patients), when the viral burden may still be too low to be identified by traditional techniques. Because of its sensitivity, PCR can also often detect asymptomatic carriers and may remain positive even days after an infection has clinically resolved.[3][43]
  • Multi-pathogen panels are also available, which can detect the presence of multiple viral infections (including RSV) in a single person.[3]

Viral culture

edit

In traditional viral culture, a sample of the virus is introduced to different cell lines and allowed to replicate so it can be studied. Benefits of this technique include the ability to perform genetic characterization, strain typing, and antiviral susceptibility testing. However, it is limited by its prolonged turnaround time of 3–7 days, making it less common in patient care and more common in research settings.[3]

Serologic testing

edit

Serology (the measurement of virus-specific antibodies in the serum) is not frequently used in RSV diagnosis. The time required for the body to mount a significant serologic response (and demonstrate a significant rise in antibodies that can be detected in serum) is usually not useful in guiding patient care.[2] Up to 30% of patients with documented RSV infection will have negative serology results.[43] As such, this method is generally reserved for research and surveillance studies.[2]

Imaging findings

edit
 
X-ray of a child with RSV bronchiolitis showing the typical bilateral perihilar fullness

Chest X-rays findings in children with RSV bronchiolitis are generally nonspecific and include perihilar markings, patchy hyperinflation, and atelectasis.[20] However, the American Academy of Pediatrics (AAP) does not recommend routine imaging for children with presumed RSV bronchiolitis because it does not change clinical outcomes and is associated with increased antibiotic use.[20][5] Chest X-ray is sometimes considered when the diagnosis of bronchiolitis is unclear or when there is an unexpected worsening.[5] In adults with RSV infection, chest films are often normal or demonstrate nonspecific changes consistent with viral pneumonia, such as patchy bilateral infiltrates.[44]

Differential diagnosis

edit

The differential diagnosis for individuals presenting with signs and symptoms of upper and lower respiratory tract infection includes other viral infections (such as rhinovirus, metapneumovirus, and influenza) and primary bacterial pneumonia. In children, inhaled foreign bodies and congenital conditions such as cystic fibrosis or asthma are typically considered.[3]

Prevention

edit

General prevention measures

edit

The main prevention measure is to avoid close contact with infected individuals.[5] Airborne precautions such as respirators, ventilation, and HEPA/high MERV filters, are likely protective against RSV-laden aerosols.[9]

Vaccines

edit
Main article: Respiratory syncytial virus vaccine

There is interest and research in RSV vaccine discovery, given the virus's disease burden and the lack of disease-specific therapies.[45] Vaccine development has faced obstacles that have blocked its progress. Among these are infant-specific factors, such as the immature infant immune system and the presence of maternal antibodies, which make infantile immunization difficult.[3]

RSV infection is widespread in early childhood, contributing significantly to global disease burden. The association between severe childhood infections and subsequent respiratory issues is not fully understood, particularly the suggested link between bronchiolitis, recurrent infantile wheeze, and childhood asthma. Unlike other vaccine-preventable respiratory pathogens, RSV has proven challenging for vaccine development. Ongoing efforts focus on creating vaccines that confer durable protection, with field trials eagerly anticipated. Currently, supportive care is the mainstay for treating RSV disease, as effective vaccines and antiviral drugs are awaited. The introduction of antivirals and vaccines, coupled with advanced diagnostic techniques, holds promise for reducing RSV's global impact in the coming years. These interventions may alter infection dynamics and weaken RSV's hold on communities worldwide.[3]

Potential vaccines being researched fall into five broad categories: live-attenuated, protein subunit, vector-based, virus particle subunit, and messenger RNA. Each targets different immune responses, and thus may be better suited to prevent disease in different at-risk groups. Live-attenuated vaccines have shown some success in RSV-naive infants. Other vaccine candidates hope to target vulnerable populations across the lifespan, including pregnant women and the elderly.[46][3]

 
F-specific antibodies can be given directly to young children as monoclonal antibodies (mAbs) or acquired through transplacental transfer from mother to child after maternal immunization to protect them. Adenoviruses expressing F or live-attenuated viruses will be used to vaccinate older infants and young children against RSV disease.Modified after Karron 2021[47] The RSV fusion protein (F) plays a crucial role in facilitating virus entry by mediating the fusion of viral and host cell membranes. This process involves the transformation of F from a less stable prefusion conformation to a more energetically favorable postfusion state. Antibodies directed against the F protein have demonstrated the ability to hinder viral entry and mitigate RSV-induced diseases. There has been a growing identification of antibodies specifically targeting the prefusion conformation of F. These antibodies exhibit heightened RSV-neutralizing efficacy compared to those binding to F in its postfusion state.[48]

The primary pharmaceutical developers, GSK and Pfizer, obtained Food and Drug Administration (FDA) approval for RSV vaccines targeting adults aged 60 and above. GSK's Arexvy boasts 94% efficacy against severe and 83% against symptomatic RSV in this age group, while Pfizer's Abrysvo is 86% effective against severe symptoms and 67% against symptomatic disease in adults aged 60 and older.[49]

Addressing the more challenging aspect, the need for a newborn vaccine, researchers employed a pregnancy-administered approach to protect infants during the first six months, a critical period for RSV susceptibility.[49] The FDA's advisory committee endorsed Pfizer's parental RSV vaccine, acknowledging its 82% effectiveness against severe RSV in newborns up to three months and 69% efficacy through six months. While unanimous in favor of efficacy, the committee voted 10 to 4 for safety, with concerns about a slightly higher premature birth rate in the vaccinated group. GSK halted its own trial due to a 38% higher likelihood of premature births in the vaccine group.[49]

 
Immunization, both active and passive. The fusion (F) protein is the foundation of passive immunization against the respiratory syncytial virus (RSV). Modified after Karron 2021.[47]

In May 2023, the US Food and Drug Administration (FDA) approved the first RSV vaccines, Arexvy (developed by GSK plc) and Abrysvo (Pfizer).[10][11] Mresvia is an mRNA vaccine that was approved for medical use in the United States in May 2024.[50][51][52]

Immunoprophylaxis

edit
See also: Palivizumab and Nirsevimab

Historically, RSV-specific intravenous immunoglobin (IVIG) was used to provide passive immunity to prevent RSV infection and hospitalization in the highest risk infants. This involved monthly administration of RSV-neutralizing antibodies (or immunoglobins) from human donors recovering from the disease. While this transfer of antibodies was reasonably effective in providing short-term immunization to at-risk infants, it was limited by both its intravenous administration and cost.[53]

RSV-IVIG has since been replaced with the use of a monoclonal antibody (MAb) that can be delivered through muscular injection. Palivizumab (Synagis) is a monoclonal antibody directed against the surface fusion (F) protein of the RSV virus. It was licensed in 1998 and is effective in providing temporary prophylaxis against both RSV A and B. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. Palivizumab has been shown to reduce both hospitalization rates and all-cause mortality in certain groups of high-risk children (such as those with chronic lung disease, congenital heart disease, and those born preterm).[38][54] However, its cost limits its use in many parts of the world. More potent derivatives of this antibody have since been developed (including motavizumab) but were associated with considerable adverse events.[55]

The American Academy of Pediatrics (AAP 2014) recommends RSV prophylaxis with palivizumab during RSV season for:[5]

Per AAP guidelines, palivizumab prophylaxis may also be considered in infants with:[5]

Nirsevimab (Beyfortus) is another antiviral monoclonal antibody, that has been approved for the prevention of RSV lower respiratory tract disease in newborns and infants during their first RSV season.[56] Nirsevimab requires only one dose that lasts the entire RSV season, unlike palivizumab, which has to be injected about once a month for up to four times to remain effective.[12] Nirsevimab was approved for medical use in the European Union[57][58] and the United Kingdom[59] in November 2022, and in Canada in April 2023.[12]

Treatment

edit

Supportive care

edit

Treatment for RSV infection is focused primarily on supportive care. This may include monitoring a patient's breathing or using suction to remove secretions from the upper airway. Supplemental oxygen may also be delivered through a nasal cannula or face mask in order to improve airflow. In severe cases of respiratory failure, intubation and mechanical ventilation may be required to support breathing. If signs of dehydration are present, fluids may also be given orally or through an IV.[53]

Additional supportive treatments have been investigated in infants hospitalized with RSV bronchiolitis. These include:

  • Nebulized hypertonic saline has been shown to reduce length of hospitalization and reduce clinical severity in infants with viral bronchiolitis. A possible mechanism is reduced airway edema and mucus plugging to decrease airway obstruction.[60][61]
  • Heliox, a mixture of oxygen with helium, may reduce respiratory distress within the first hour of treatment. It works by decreasing airway resistance and easing the work of breathing. However, it has not been shown to affect overall illness outcomes.[62]
  • Chest physiotherapy including forced respiratory techniques for infants has not been found to reduce disease severity or yield any other improvement.[63] Evidence supporting other physiotherapy approaches including instrumental physiotherapy and rhinopharyngeal retrograde technique (RRT) is very limited, The effects and any potential use needs further assessment in clinical trials.[63] There is also no evidence to support hypertonic saline therapy combined with chest physiotherapy.[63] There is very weak evidence to suggest that passive slow expiratory technique physiotherapy may contribute to a "mild to moderate" positive change in the severity of bronchiolitis for hospitalized infants, however the benefit of this approach for infants treated in ambulatory settings is not known.[63]
  • Inhaled recombinant human deoxyribonuclease (rhDNase), an enzyme that digests the DNA that contributes to mucus plugging and airway obstruction, has not been shown to improve clinical outcomes in this group.

Viral-specific therapies

edit
  • Ribavirin is an antiviral medication licensed for the treatment of RSV in children.[13] It is a guanosine analog that acts by inhibiting viral RNA synthesis and capping. It was approved in 1986 for treatment of RSV infection. However, the use of ribavirin remains controversial due to unclear evidence of efficacy and concerns about toxicity to exposed staff members, as well as cost.[13][64] As such, treatment guidelines do not make recommendations for its use in children. In adults, ribavirin is used off-label and is generally reserved for the severely immunocompromised, such as those undergoing hematopoietic stem cell transplants.[3]
  • Presatovir, an experimental antiviral drug, has shown promising results in clinical trials but has not yet been approved for medical use. It acts as a fusion inhibitor by inhibiting the RSV F protein.[65]
  • Immunoglobins, both RSV-specific and non-specific, have historically been used for RSV-related illness. However, there is insufficient evidence to support the use of immunoglobins in children with RSV infection.[66]

Anti-inflammatories

edit
  • Corticosteroids (systemic or inhaled) have not been found to decrease hospitalization length or disease severity in viral bronchiolitis.[67] Their use may also prolong viral shedding, and thus is not commonly recommended. However, the use of oral corticosteroids remains common in adults with RSV-related exacerbation of underlying lung disease.[3]
  • Leukotriene inhibitors such as montelukast have been used in the treatment of infants and children with bronchiolitis. However, the evidence supporting their use remains inconsistent with no definitive conclusions on their efficacy.[68]

Bronchodilators

edit

Bronchodilators, medications commonly used to treat asthma, are sometimes used to treat the wheezing associated with RSV infection. These medications (such as albuterol or salbutamol) are beta-agonists that relax the muscles of the airways to allow for improved airflow. However, bronchodilators have not been found to improve clinical severity of infection or rate of hospitalization among those with RSV infection. Given their limited benefit, plus their adverse event profile, they are not routinely recommended for use in RSV bronchiolitis.[53][67]

Antibiotics

edit

Antibiotic therapy is not appropriate for treatment of RSV-related bronchiolitis or viral pneumonia.[69] Antibiotics target bacterial pathogens, not viral pathogens such as RSV. However, antibiotics may be considered if there is clear evidence that a secondary bacterial infection has developed. Ear infections may also develop in a small number of infants with RSV bronchiolitis, in which case oral antibiotics may sometimes be used.[53]

Beyond vaccines, AstraZeneca and Sanofi introduced nirsevimab, a prophylactic monoclonal antibody with 75% efficacy against RSV cases in infants under one year. Europe approved nirsevimab in November 2022, and the FDA followed suit in July 2023. Merck's clesrovimab, a similar monoclonal antibody, is in late-stage trials.[49]

Epidemiology

edit

Infants and children

edit

Worldwide, RSV is the leading cause of bronchiolitis and pneumonia in infants and children under the age of 5. The risk of serious infection is highest during the first 6 months of life. Of those infected with RSV, 2–3% will develop bronchiolitis, necessitating hospitalization.[70] Each year, approximately 30 million acute respiratory illnesses and over 60,000 childhood deaths are caused by RSV worldwide. An estimated 87% of infants will have experienced an RSV infection by the age of 18 months, and nearly all children will have been infected by 3 years. In the United States, RSV is responsible for up to 20% of acute respiratory infection hospitalizations in children under the age of 5. However, the vast majority of RSV-related deaths occur in low-income countries that lack access to basic supportive care.[3]

The prophylactic use of palivizumab or nirsevimab (both are monoclonal antibody treatments) can prevent RSV infection in high-risk infants. Passive immunization is available to prevent RSV infection and hospitalization in the highest risk infants.

A 2024 JAMA Open article suggested a rise in sudden unexpected infant deaths (SUID) may be connected to an unusual surge of RSV in 2021.[71] Researchers analyzed over 14,000 SUID cases using CDC records and found that the rate per 100,000 live births increased by 10% between 2019 and 2021.[72] The study revealed that the risk of SUID was highest from June to December 2021, coinciding with an off-season spike in RSV hospitalizations after the virus deviated from its typical winter pattern in 2020.[73]

Adults

edit

It is rare for healthy young adults to develop severe illness requiring hospitalization from RSV. However, it is now recognized as a significant cause of morbidity and mortality in certain adult populations, including the elderly and those with underlying heart or lung diseases. Its clinical impact among elderly adults is estimated to be similar to that of influenza.[26] Each year, approximately 5–10% of nursing home residents will experience RSV infection, with significant rates of pneumonia and death. RSV is also responsible for 2–5% of adult community-acquired pneumonias.[26]

Immunocompromised

edit

In both adults and children, immunosuppression increases susceptibility to RSV infection. Children living with HIV are more likely to develop acute illness, and are 3.5 times more likely to require hospitalization than children without HIV.[3] Bone marrow transplant patients prior to marrow engraftment are at particularly high risk, with RSV accounting for nearly half of the viral infections in this population. This group has also demonstrated mortality rates of up to 80% among those with RSV pneumonia.[26] While infection may occur within the community, hospital-acquired infection is thought to account for 30–50% of cases among immunocompromised individuals.[26]

Seasonality

edit

RSV seasonality varies around the world. In temperate climates, infection rates tend to be highest during the cold winter months. This is often attributed to increased indoor crowding and increased viral stability in the lower temperatures. In tropical and arctic climates, however, the annual variation is less well defined and seems to be more prevalent during the rainy season.[2][3] Annual epidemics are generally caused by the presence of several different viral strains. Subtype A and B viruses will often circulate simultaneously within a specific geographic region, although group A viruses are more prevalent.[26]

Research

edit

A study investigated RSV-specific T cell responses in " 55 infants hospitalized for RSV bronchiolitis and found that these responses were similar during both acute illness and recovery, and did not increase after subsequent RSV infections.[41] This suggests that RSV-specific T-cell responses may not prevent reinfection and might not expand effectively in the body after reinfection. However, it's possible that these cells could be located in specific areas of the lungs and respond more strongly to secondary infection, as seen in animal studies. For instance, a study using mice showed that the "extent of the BALF inflammatory response to reinfection response to reinfection in adulthood is determined by the age at first infection."[41] The study also discovered that the patterns differ for "neonatal infection primes the host to develop a Th2-biased response."[41] The exact mechanisms behind this phenomenon remain unclear. One possibility is that a lack of IFN-γ production in newborns during their first encounter with RSV, possibly due to an immature immune system, allows for the emergence of a Th2-biased response that persists and can be triggered again during subsequent RSV infections.[41] However, it's improbable that variations solely in IFN-γ levels explain this susceptibility window. IL-13 appears to play a significant role as a regulator in this process. IL-13 is a protein located in the lung. It is a "mediator of allergic asthma" and it is in charge of "regulating eosinophilic inflammation, mucus secretion, and airway hyperresponsiveness."[74]

SARS-CoV-2 infections, the virus responsible for COVID-19, may lead to a higher risk of infection with RSV.[75] In November 2022, the RSV hospitalization rate for newborns was seven times the rate in 2018.[citation needed] This, combined with increasing influenza circulation, caused the US state of Oregon to declare a state of emergency.[citation needed] The Children's Hospital Association and the American Academy of Pediatrics asked US President Joe Biden to declare a state of emergency.[76]

The findings of a 2024 cross-sectional study of 6,248 hospitalized adults with RSV infection suggest that acute cardiac events are common among hospitalized older adults with RSV infection, and are associated with severe clinical outcomes. Nearly a quarter of hospitalized people over 50 with RSV experienced an acute cardiac event (most frequently acute heart failure), including 1 in 12 adults (8.5%) without documented underlying cardiovascular disease. Patients who had acute cardiac events had nearly twice the risk of a severe outcome than patients who did not.[77][78]

Notes

edit
  1. ^ The second word, syncytial, is pronounced /sɪnˈsɪʃəl/.

References

edit
  1. ^ "ICTV Taxonomy history: Human orthopneumovirus". International Committee on Taxonomy of Viruses (ICTV). Archived from the original on 25 September 2022. Retrieved 27 December 2018.
  2. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab Griffiths C, Drews SJ, Marchant DJ (January 2017). "Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment". Clinical Microbiology Reviews. 30 (1): 277–319. doi:10.1128/CMR.00010-16. PMC 5217795. PMID 27903593.
  3. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at Jha A, Jarvis H, Fraser C, Openshaw PJ (June 2016). "Chapter 5: Respiratory Syncytial Virus". In Hui DS, Rossi GA, Johnston SL (eds.). SARS, MERS and other Viral Lung Infections. Wellcome Trust–Funded Monographs and Book Chapters. Sheffield (UK): European Respiratory Society. ISBN 978-1-84984-070-5. PMID 28742304. Archived from the original on 28 December 2020. Retrieved 29 October 2020.
  4. ^ a b c d e f g h i j k l m n o p q Coultas JA, Smyth R, Openshaw PJ (October 2019). "Respiratory syncytial virus (RSV): a scourge from infancy to old age". Thorax. 74 (10): 986–993. doi:10.1136/thoraxjnl-2018-212212. hdl:10044/1/73848. PMID 31383776. S2CID 199449874.
  5. ^ a b c d e f g h Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. (November 2014). "Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis". Pediatrics. 134 (5): e14741–502. doi:10.1542/peds.2014-2742. PMID 25349312. S2CID 3192188.
  6. ^ Kulkarni H, Smith CM, Lee Ddo H, Hirst RA, Easton AJ, O'Callaghan C (August 2016). "Evidence of Respiratory Syncytial Virus Spread by Aerosol. Time to Revisit Infection Control Strategies?". American Journal of Respiratory and Critical Care Medicine. 194 (3): 308–316. doi:10.1164/rccm.201509-1833OC. PMID 26890617.
  7. ^ Stadnytskyi V, Bax CE, Bax A, Anfinrud P (June 2020). "The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission". Proceedings of the National Academy of Sciences. 117 (22): 11875–11877. Bibcode:2020PNAS..11711875S. doi:10.1073/pnas.2006874117. PMC 7275719. PMID 32404416.
  8. ^ Zayas G, Chiang MC, Wong E, MacDonald F, Lange CF, Senthilselvan A, et al. (December 2012). "Cough aerosol in healthy participants: fundamental knowledge to optimize droplet-spread infectious respiratory disease management". BMC Pulmonary Medicine. 12 (1): 11. doi:10.1186/1471-2466-12-11. PMC 3331822. PMID 22436202.
  9. ^ a b c Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, et al. (August 2021). "Airborne transmission of respiratory viruses". Science. 373 (6558). doi:10.1126/science.abd9149. PMC 8721651. PMID 34446582.
  10. ^ a b "FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine" (Press release). U.S. Food and Drug Administration (FDA). 3 May 2023. Archived from the original on 4 May 2023. Retrieved 3 May 2023.
  11. ^ a b "US FDA approves Pfizer's RSV vaccine". Reuters. 31 May 2023. Retrieved 1 June 2023.
  12. ^ a b c "Health Canada approves new antibody drug to help prevent serious RSV in babies". CTVNews. 22 April 2023. Archived from the original on 24 April 2023. Retrieved 24 April 2023.
  13. ^ a b c Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Griffiths P, et al. (March 2015). "Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics". Journal of Infectious Diseases. 211 (suppl 1): S1–S20. doi:10.1093/infdis/jiu828. PMC 4345819. PMID 25713060.
  14. ^ Blount RE, Morris JA, Savage RE (July 1956). "Recovery of cytopathogenic agent from chimpanzees with coryza" (PDF). Proceedings of the Society for Experimental Biology and Medicine. 92 (3): 544–549. doi:10.3181/00379727-92-22538. PMID 13359460. S2CID 29764422. Archived from the original on 2 February 2023. Retrieved 2 February 2023.
  15. ^ Chanock R, Roizman B, Myers R (November 1957). "Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization". American Journal of Hygiene. 66 (3): 281–290. doi:10.1093/oxfordjournals.aje.a119901. PMID 13478578. S2CID 4529751.
  16. ^ Chanock R, Finberg L (November 1957). "Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children". American Journal of Hygiene. 66 (3): 291–300. doi:10.1093/oxfordjournals.aje.a119902. PMID 13478579.
  17. ^ Walsh EE, Hall CB (January 2015). "Chapter 160 Respiratory Syncytial Virus (RSV)". In Bennett JE, Dolin R, Blaser MJ (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth ed.). Philadelphia: Elsevier. pp. 1948–1960.e3. doi:10.1016/B978-1-4557-4801-3.00160-0. ISBN 978-1-4557-4801-3.
  18. ^ Afonso CL, Amarasinghe GK, Bányai K, Bào Y, Basler CF, Bavari S, et al. (August 2016). "Taxonomy of the order Mononegavirales: update 2016". Archives of Virology. 161 (8): 2351–2360. doi:10.1007/s00705-016-2880-1. PMC 4947412. PMID 27216929.
  19. ^ a b c d e f g Borchers AT, Chang C, Gershwin ME, Gershwin LJ (December 2013). "Respiratory syncytial virus--a comprehensive review". Clinical Reviews in Allergy & Immunology. 45 (3): 331–379. doi:10.1007/s12016-013-8368-9. PMC 7090643. PMID 23575961.
  20. ^ a b c d e f Smith DK, Seales S, Budzik C (January 2017). "Respiratory Syncytial Virus Bronchiolitis in Children". American Family Physician. 95 (2): 94–99. PMID 28084708. Archived from the original on 16 April 2021. Retrieved 3 November 2020.
  21. ^ AAP Committee on Infectious Diseases (2018). Kimberlin DW, Brady MT, Jackson MA (eds.). Red Book (2018): 2018–2021 report of the Committee on Infectious Diseases (31st ed.). doi:10.1542/9781610021470. ISBN 978-1-61002-147-0. OCLC 1035556489.[page needed]
  22. ^ a b Friedman JN, Rieder MJ, Walton JM (November 2014). "Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age". Paediatrics & Child Health. 19 (9): 485–498. doi:10.1093/pch/19.9.485. PMC 4235450. PMID 25414585.
  23. ^ "RSV Symptoms and Care". U.S. Centers for Disease Control and Prevention (CDC). 4 February 2019. Archived from the original on 3 September 2021. Retrieved 28 October 2020.
  24. ^ a b Hijano DR, Maron G, Hayden RT (December 2018). "Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant". Frontiers in Microbiology. 9: 3097. doi:10.3389/fmicb.2018.03097. PMC 6299032. PMID 30619176.
  25. ^ Walsh EE (March 2017). "Respiratory Syncytial Virus Infection: An Illness for All Ages". Clinics in Chest Medicine. 38 (1): 29–36. doi:10.1016/j.ccm.2016.11.010. PMC 5844562. PMID 28159159.
  26. ^ a b c d e f g h i Falsey AR, Walsh EE (July 2000). "Respiratory syncytial virus infection in adults". Clinical Microbiology Reviews. 13 (3): 371–384. doi:10.1128/cmr.13.3.371-384.2000. PMC 88938. PMID 10885982.
  27. ^ Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (April 2005). "Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults". The New England Journal of Medicine. 352 (17): 1749–1759. doi:10.1056/nejmoa043951. PMID 15858184.
  28. ^ a b c "Learn about RSV in older adults with chronic medical conditions". U.S. Centers for Disease Control and Prevention (CDC). 1 March 2024. Retrieved 25 April 2024.
  29. ^ Jartti T, Gern JE (October 2017). "Role of viral infections in the development and exacerbation of asthma in children". The Journal of Allergy and Clinical Immunology. 140 (4): 895–906. doi:10.1016/j.jaci.2017.08.003. PMC 7172811. PMID 28987219.
  30. ^ Castro-Rodriguez JA, Forno E, Rodriguez-Martinez CE, Celedón JC (2016). "Risk and Protective Factors for Childhood Asthma: What Is the Evidence?". The Journal of Allergy and Clinical Immunology. In Practice. 4 (6): 1111–1122. doi:10.1016/j.jaip.2016.05.003. PMC 5107168. PMID 27286779.
  31. ^ Saravanos GL, King CL, Deng L, Dinsmore N, Ramos I, Takashima M, et al. (December 2021). "Respiratory Syncytial Virus–Associated Neurologic Complications in Children: A Systematic Review and Aggregated Case Series". The Journal of Pediatrics. 239: 39–49.e9. doi:10.1016/j.jpeds.2021.06.045. hdl:10072/405721. PMID 34181989. S2CID 235672947.
  32. ^ Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. (December 2015). "Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis". Journal of Global Health. 5 (2): 020416. doi:10.7189/jogh.05.020416. PMC 4676580. PMID 26682048.
  33. ^ Khawaja F, Chemaly RF (July 2019). "Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies". Haematologica. 104 (7): 1322–1331. doi:10.3324/haematol.2018.215152. PMC 6601091. PMID 31221784.
  34. ^ "Respiratory syncytial virus". Johns Hopkins ABX Guide. Archived from the original on 1 November 2020. Retrieved 29 October 2020.
  35. ^ "Genus: Orthopneumovirus – Pneumoviridae – Negative-sense RNA Viruses". International Committee on Taxonomy of Viruses (ICTV). Archived from the original on 3 June 2021. Retrieved 29 October 2020.
  36. ^ a b Cowton VM, McGivern DR, Fearns R (July 2006). "Unravelling the complexities of respiratory syncytial virus RNA synthesis". The Journal of General Virology. 87 (Pt 7): 1805–1821. doi:10.1099/vir.0.81786-0. PMID 16760383.
  37. ^ a b c d e f g h i Collins PL, Fearns R, Graham BS (2013). "Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease". Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology. Vol. 372. pp. 3–38. doi:10.1007/978-3-642-38919-1_1. ISBN 978-3-642-38918-4. PMC 4794264. PMID 24362682.
  38. ^ a b c Drysdale SB, Green CA, Sande CJ (April 2016). "Best practice in the prevention and management of paediatric respiratory syncytial virus infection". Therapeutic Advances in Infectious Disease. 3 (2): 63–71. doi:10.1177/2049936116630243. PMC 4784570. PMID 27034777.
  39. ^ a b "RSV Transmission". U.S. Centers for Disease Control and Prevention (CDC). 4 February 2019. Archived from the original on 29 October 2020. Retrieved 9 November 2020.
  40. ^ a b c d Carvajal JJ, Avellaneda AM, Salazar-Ardiles C, Maya JE, Kalergis AM, Lay MK (September 2019). "Host Components Contributing to Respiratory Syncytial Virus Pathogenesis". Frontiers in Immunology. 10: 2152. doi:10.3389/fimmu.2019.02152. PMC 6753334. PMID 31572372.
  41. ^ a b c d e f g h i j Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, Miyahara N, et al. (August 2005). "The Enhancement or Prevention of Airway Hyperresponsiveness during Reinfection with Respiratory Syncytial Virus Is Critically Dependent on the Age at First Infection and IL-13 Production". The Journal of Immunology. 175 (3): 1876–1883. doi:10.4049/jimmunol.175.3.1876. PMID 16034131.
  42. ^ a b c d e f g Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. (April 2020). "Recent advances in the detection of respiratory virus infection in humans". Journal of Medical Virology. 92 (4): 408–417. doi:10.1002/jmv.25674. PMC 7166954. PMID 31944312.
  43. ^ a b c d Henrickson KJ, Hall CB (November 2007). "Diagnostic assays for respiratory syncytial virus disease". The Pediatric Infectious Disease Journal. 26 (11 Suppl): S36–40. doi:10.1097/INF.0b013e318157da6f. PMID 18090198. S2CID 205692472.
  44. ^ Chien JW, Johnson JL (March 2000). "Viral pneumonias. Epidemic respiratory viruses". Postgraduate Medicine. 107 (3): 41–42, 45–47, 51–52. doi:10.3810/pgm.2000.03.941. PMID 10728134. S2CID 33643168.
  45. ^ Carbonell-Estrany X, Rodgers-Gray BS, Paes B (3 April 2021). "Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries". Expert Review of Anti-infective Therapy. 19 (4): 419–441. doi:10.1080/14787210.2021.1828866. ISSN 1478-7210.
  46. ^ Battles MB, McLellan JS (April 2019). "Respiratory syncytial virus entry and how to block it". Nature Reviews. Microbiology. 17 (4): 233–245. doi:10.1038/s41579-019-0149-x. PMC 7096974. PMID 30723301.
  47. ^ a b Karron RA (May 2021). "Preventing respiratory syncytial virus (RSV) disease in children". Science. 372 (6543): 686–687. Bibcode:2021Sci...372..686K. doi:10.1126/science.abf9571. PMID 33986169. S2CID 234487273.
  48. ^ Rossey I, McLellan JS, Saelens X, Schepens B (March 2018). "Clinical Potential of Prefusion RSV F-specific Antibodies". Trends in Microbiology. 26 (3): 209–219. doi:10.1016/j.tim.2017.09.009. PMID 29054341.
  49. ^ a b c d Haelle T. "RSV Vaccines Are Nearly Here after Decades of False Starts - Decades of failed attempts have given way to several successful vaccines and treatments for the respiratory disease RSV". Scientific American. Archived from the original on 12 April 2023. Retrieved 13 April 2023.
  50. ^ "Mresvia- respiratory syncytial virus vaccine suspension". DailyMed. 31 May 2024. Retrieved 16 June 2024.
  51. ^ "Mresvia Respiratory Syncytial Virus Vaccine, mRNA (mRNA-1345)". U.S. Food and Drug Administration. 31 May 2024. Archived from the original on 2 June 2024. Retrieved 2 June 2024.
  52. ^ "Moderna Receives U.S. FDA Approval for RSV Vaccine Mresvia" (Press release). Moderna. 31 May 2024. Archived from the original on 31 May 2024. Retrieved 31 May 2024 – via Accesswire.
  53. ^ a b c d Kaslow RA, Stanberry LR, LeDuc JW (2014). Viral infections of humans: Epidemiology and control (Fifth ed.). New York: Springer. pp. 601–610. ISBN 978-1-4899-7448-8. OCLC 891646285.
  54. ^ Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B (April 2013). "Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children". The Cochrane Database of Systematic Reviews (4): CD006602. doi:10.1002/14651858.CD006602.pub4. PMID 23633336.
  55. ^ Jares Baglivo S, Polack FP (May 2019). "The long road to protect infants against severe RSV lower respiratory tract illness". F1000Research. 8: 610. doi:10.12688/f1000research.18749.1. PMC 6498742. PMID 31105933.
  56. ^ "New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection". European Medicines Agency. 16 September 2022. Archived from the original on 19 September 2022. Retrieved 24 April 2023.
  57. ^ "Beyfortus". Union Register of medicinal products. 3 November 2022. Archived from the original on 6 November 2022. Retrieved 6 November 2022.
  58. ^ "Beyfortus approved in the EU for the prevention of RSV lower respiratory tract disease in infants". AstraZeneca (Press release). 4 November 2022. Archived from the original on 6 November 2022. Retrieved 6 November 2022.
  59. ^ "MHRA Grants Approval of Beyfortus (nirsevimab) for Prevention of RSV Disease in Infants" (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 9 November 2022. Archived from the original on 13 April 2023. Retrieved 13 April 2023 – via Business Wire.
  60. ^ Wang ZY, Li XD, Sun AL, Fu XQ (August 2019). "Efficacy of 3% hypertonic saline in bronchiolitis: A meta-analysis". Experimental and Therapeutic Medicine. 18 (2): 1338–1344. doi:10.3892/etm.2019.7684. PMC 6639771. PMID 31384334.
  61. ^ Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP (31 July 2013). "Nebulised hypertonic saline solution for acute bronchiolitis in infants". The Cochrane Database of Systematic Reviews (7): CD006458. doi:10.1002/14651858.CD006458.pub3. PMID 23900970.
  62. ^ Liet JM, Ducruet T, Gupta V, Cambonie G, et al. (Cochrane Acute Respiratory Infections Group) (September 2015). "Heliox inhalation therapy for bronchiolitis in infants". The Cochrane Database of Systematic Reviews. 2015 (9): CD006915. doi:10.1002/14651858.CD006915.pub3. PMC 8504435. PMID 26384333.
  63. ^ a b c d Roqué-Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C, Vilaró J (April 2023). "Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old". The Cochrane Database of Systematic Reviews. 2023 (4): CD004873. doi:10.1002/14651858.CD004873.pub6. PMC 10070603. PMID 37010196.
  64. ^ Ventre K, Randolph AG (January 2007). Ventre K (ed.). "Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children". The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446.
  65. ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.
  66. ^ Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP (October 2023). "Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection". The Cochrane Database of Systematic Reviews. 2023 (10): CD009417. doi:10.1002/14651858.CD009417.pub3. PMC 10591280. PMID 37870128.
  67. ^ a b Gadomski AM, Scribani MB (June 2014). "Bronchodilators for bronchiolitis". The Cochrane Database of Systematic Reviews. 2014 (6): CD001266. doi:10.1002/14651858.CD001266.pub4. PMC 7055016. PMID 24937099.
  68. ^ Liu F, Ouyang J, Sharma AN, Liu S, Yang B, Xiong W, et al. (March 2015). "Leukotriene inhibitors for bronchiolitis in infants and young children". The Cochrane Database of Systematic Reviews. 2015 (3): CD010636. doi:10.1002/14651858.cd010636.pub2. PMC 10879915. PMID 25773054.
  69. ^ Farley R, Spurling GK, Eriksson L, Del Mar CB, et al. (Cochrane Acute Respiratory Infections Group) (October 2014). "Antibiotics for bronchiolitis in children under two years of age". The Cochrane Database of Systematic Reviews. 2014 (10): CD005189. doi:10.1002/14651858.CD005189.pub4. PMC 10580123. PMID 25300167.
  70. ^ Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. (February 2009). "The burden of respiratory syncytial virus infection in young children". The New England Journal of Medicine. 360 (6): 588–598. doi:10.1056/NEJMoa0804877. PMC 4829966. PMID 19196675.
  71. ^ Gummerson S. "Researchers investigate potential link between RSV and sudden unexpected infant deaths". ABC News. Retrieved 28 September 2024.
  72. ^ Guare EG, Zhao R, Ssentongo P, Batra EK, Chinchilli VM, Paules CI (26 September 2024). "Rates of Sudden Unexpected Infant Death Before and During the COVID-19 Pandemic". JAMA Network Open. 7 (9): e2435722. doi:10.1001/jamanetworkopen.2024.35722. ISSN 2574-3805. PMID 39325450.
  73. ^ Guare EG, Zhao R, Ssentongo P, Batra EK, Chinchilli VM, Paules CI (26 September 2024). "Rates of Sudden Unexpected Infant Death Before and During the COVID-19 Pandemic". JAMA Network Open. 7 (9): e2435722. doi:10.1001/jamanetworkopen.2024.35722. ISSN 2574-3805. PMID 39325450.
  74. ^ Zhou X, Jiang M, Wang F, Qian Y, Song Q, Sun Y, et al. (January 2023). "Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation". Frontiers in Immunology. 13. doi:10.3389/fimmu.2022.1084139. PMC 9871593. PMID 36703972.
  75. ^ Wang L, Davis PB, Berger N, Kaelber DC, Volkow N, Xu R (October 2023). "Association of COVID-19 with respiratory syncytial virus (RSV) infections in children aged 0–5 years in the USA in 2022: a multicentre retrospective cohort study". Family Medicine and Community Health. 11 (4): e002456. doi:10.1136/fmch-2023-002456. PMC 10582888. PMID 37832975.
  76. ^ Kimball S (18 November 2022). "Children's hospitals call on Biden to declare emergency in response to 'unprecedented' RSV surge". CNBC. Archived from the original on 21 November 2022. Retrieved 20 November 2022.
  77. ^ Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. (June 2024). "Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection". JAMA Internal Medicine. 184 (6): 602–611. doi:10.1001/jamainternmed.2024.0212. PMC 11019447. PMID 38619857.
  78. ^ Eckert N (16 May 2024). "RSV Infection Raises Risk for Acute Cardiovascular Events". Medscape.

Further reading

edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Respiratory_syncytial_virus&oldid=1254119568"